Zevra Therapeutics (ZVRA) to Release Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) is expected to be releasing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Zevra Therapeutics to post earnings of $0.06 per share and revenue of $31.96 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Zevra Therapeutics Stock Down 0.0%

Shares of ZVRA traded down $0.00 on Monday, reaching $10.07. The company’s stock had a trading volume of 562,903 shares, compared to its average volume of 1,002,576. The company has a current ratio of 5.68, a quick ratio of 5.63 and a debt-to-equity ratio of 0.40. Zevra Therapeutics has a twelve month low of $7.16 and a twelve month high of $13.16. The stock has a market capitalization of $595.22 million, a PE ratio of 7.57 and a beta of 0.88. The firm has a fifty day moving average of $9.60 and a 200-day moving average of $9.26.

Insider Activity

In other Zevra Therapeutics news, SVP Timothy J. Sangiovanni sold 3,000 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the sale, the senior vice president owned 29,590 shares in the company, valued at approximately $271,636.20. This trade represents a 9.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joshua Schafer sold 10,500 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the sale, the insider owned 62,278 shares of the company’s stock, valued at approximately $572,334.82. This trade represents a 14.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Man Group plc increased its stake in Zevra Therapeutics by 174.4% in the 4th quarter. Man Group plc now owns 92,347 shares of the company’s stock valued at $827,000 after buying an additional 58,695 shares during the last quarter. Rhumbline Advisers increased its stake in Zevra Therapeutics by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 83,221 shares of the company’s stock valued at $733,000 after buying an additional 8,636 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter worth approximately $631,000. Wells Fargo & Company MN increased its stake in shares of Zevra Therapeutics by 81.7% during the 4th quarter. Wells Fargo & Company MN now owns 66,950 shares of the company’s stock worth $600,000 after purchasing an additional 30,094 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter worth approximately $597,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZVRA. Weiss Ratings upgraded shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday, March 10th. Guggenheim set a $23.00 target price on shares of Zevra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 10th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, April 11th. Finally, BTIG Research began coverage on shares of Zevra Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $23.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.